



INTUITIONLABS / RESEARCH & PRACTICAL GUIDANCE

AI in Pharma: 15 Startups Accelerating Drug Discovery

Build practical AI for pharma and biotech with IntuitionLabs. We help life-science teams turn complex information and workflows into useful software, governed knowledge systems and AI tools.

Published by IntuitionLabs · 2026-03-13 · ai drug discovery · pharmaceutical r&d · biotech startups · machine learning · clinical trials · generative biology · protein engineering

Original article: <https://intuitionlabs.ai/articles/ai-drug-discovery-pharma-biotech-startups>



In this article

1. Executive Summary
2. Introduction and Background
3. The Promise of AI in Pharma Research
4. Categories of AI-Accelerated Research
5. Data and Case Studies
6. Case Studies of AI-Powered Research
7. Implications and Future Directions
8. Conclusion

Executive Summary

Pharmaceutical and biotechnology R&D is notoriously slow, risky, and expensive – typically taking over a decade and costing on the order of \$2–3 billion to bring a single new drug to market ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). Over the past several years, however, a surge of artificial intelligence (AI) startups and initiatives has set out to **dramatically accelerate** this process. These companies apply machine learning and AI methods to tasks ranging from molecular design and vaccine development to lab automation and clinical-trial management, aiming to cut development timelines, reduce failure rates, and unlock novel discoveries. Investors have poured billions into this sector: for example, the startup **Xaira Therapeutics** launched in 2024 with over \$1 billion in funding from leading biotech investors (www.axios.com). Similarly, Insitro – an AI-driven drug discovery company founded in 2018 – announced collaborations with major pharma (Eli Lilly, Bristol-Myers Squibb) to co-develop treatments, underscoring the industry's commitment (apnews.com).

This report examines 15 leading startups that exemplify how AI is being used to accelerate scientific research in pharma and biotech, combining historical case studies with selected updates through July 2026. Organizations include AI-based drug discovery platforms (e.g. **Insitro**, **Exscientia**, **BenevolentAI**, **Atomwise**), generative biology companies (e.g. **EvolutionaryScale**, **Baseimmune**, **Transcripta Bio**), automated machine-learning research (e.g. **Autoscience**, which describes a mission to automate AI research ([company overview](#))), and even firms tackling bottlenecks in later stages (e.g. **Formation Bio** for clinical trials, **Nucleus Genomics** for genetic risk assessment). Across these cases, companies report breakthroughs such as moving candidates into trials in a fraction of the usual time (time.com) (www.lemonde.fr), drastically reducing the number of compounds screened (www.lemonde.fr), or designing entirely new proteins using AI-generated evolutionary paths (elpais.com). Yet, many industry experts caution that **no AI-discovered drug has yet reached the market**, and the field is still in an early “**searching for product-market fit**” phase (www.wired.com) (www.lemonde.fr).

This report provides an in-depth analysis, with the following sections:

- **Introduction & Background:** The challenges of pharma R&D and how AI promises to help, including key statistics on timelines and costs ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)), and the rise of AI tools (e.g. protein-folding breakthroughs) that have spurred the recent surge.
- **AI in Drug Discovery:** Detailed examination of startups using AI for molecule/target discovery and design. Case studies include Insitro (apnews.com) (ML-driven discovery platform), Exscientia (www.lemonde.fr) (“precision” AI design that cut design time from years to months), and Recursion/Atomwise and others.
- **AI in Biotech Applications:** Companies applying AI to biological data and novel therapeutics. Examples: EvolutionaryScale (elpais.com) (AI language model for novel proteins), Baseimmune (www.axios.com) (AI-generated vaccines for future pathogens), Transcripta Bio (time.com) (AI-driven repurposing of existing drugs via gene expression data), among others.
- **AI & Clinical Trials / Other Bottlenecks:** Startups addressing post-discovery phases. Formation Bio (time.com) uses AI to streamline clinical trial operations, claiming up to 50% reductions in trial duration. Nucleus Genomics (www.axios.com) applies AI genomics to reproductive health, assessing disease risk

in embryos. We also survey companies like Insilico and BenevolentAI on their progress through trials (www.lemonde.fr).

- **Data-Driven Pharma and Ecosystem Trends:** Cross-cutting developments, including discussion of data integration (Owkin, BenchSci), lab automation (Autoscience (www.axios.com), Strateos), and industry movements (e.g. Recursion's November 2024 combination with Exscientia ([completion announcement](#)) (www.wired.com)). We present one summary table listing the 15 startups with key facts (see below).
- **Evidence and Outcomes:** We highlight concrete achievements (e.g. Transcripta moving five drugs to trials in ~2 years (time.com), Exscientia's lead project needing only 250 synthesized compounds vs ~5000 conventionally (www.lemonde.fr) and funding milestones (e.g. Baseimmune's £9m Series A (www.axios.com)). Insilico reported in July 2026 that rentosertib had advanced into Phase III development ([Insilico announcement](#)).
- **Implications and Future Directions:** Discussion of the broader impact, challenges (data quality, regulation (www.lemonde.fr), hype vs. reality), and future prospects (AI tools in vaccinology (www.axios.com), regulatory shifts like FDA's move to AI-based testing (www.axios.com), and the evolving startup landscape). All sections are supported by citations from the latest industry reports, news articles, and scientific literature (pmc.ncbi.nlm.nih.gov) (time.com) (www.lemonde.fr) (time.com) (www.wired.com). In total, this comprehensive report synthesizes multiple perspectives, detailed case studies, data and expert commentary to characterize how AI startups are reshaping pharma and biotech research.

Introduction and Background

Pharmaceutical innovation historically suffers from *long development timelines, steep costs, and high failure rates*. On average, bringing a new therapeutic from initial discovery to market requires **10–15 years** and on the order of **\$2–3 billion** (pmc.ncbi.nlm.nih.gov). Even when a compound does succeed, only a small fraction of early candidates ever make it through clinical trials. FDA's clinical-development overview estimates that approximately 70% of drugs in phase 1 move to phase 2, while approximately 33% of drugs in phase 2 move to phase 3 ([FDA](#)).

In recent years, emerging *artificial intelligence (AI) techniques* have been touted as key to breaking this logjam (pmc.ncbi.nlm.nih.gov) (www.axios.com). Machine learning and deep learning methods can rapidly analyze large-scale biological and chemical datasets to identify patterns invisible to human researchers. High-profile breakthroughs have demonstrated AI's potential: for instance, DeepMind's AlphaFold system in 2020 achieved near-perfect prediction of protein 3D structures (www.frontiersin.org), inaugurating a new era of "biology-as-code." Similarly, language models trained on genomic data are now being used to generate novel proteins and functional biomolecules (elpais.com).

The combination of these technical advances and historical urgency has triggered a surge of investment and startup activity. Consulting reports and media surveys in 2023–2025 counted **hundreds of new AI-focused biotech companies worldwide**. For example, Le Monde (drawing on a Boston Consulting Group study) noted over 200 AI–biotech startups globally as of 2023 (www.lemonde.fr). These include established pioneers (UK's Exscientia, BenevolentAI; US's Insilico, Atomwise; Canada's Deep Genomics) as well as younger entrants

(France's Owkin, Iktos; the newly founded Xaira; and dozens more). Indeed, an Axios report (Apr 2024) collected distinguished investors behind **Xaira Therapeutics** – founded by ex-Stanford President Marc Tessier-Lavigne – as evidence of a full-scale “AI-biotech” build-out (www.axios.com).

Table 1 (below) summarizes the 15 representative startups we cover in this report, including founding year, headquarters, AI approach, and notable achievements. The companies span a broad range of applications: some specialize in *drug discovery and design* (Insitro, Exscientia, Atomwise, BenevolentAI, Recursion), others in *synthetic biology and protein engineering* (EvolutionaryScale, Strateos), *vaccine development* (Baseimmune), *genomic analysis* (Nucleus Genomics), *clinical trial acceleration* (Formation Bio), and *automation of foundational research* (Transcripta, Autoscience). Despite this diversity, all share the common aim of **speeding up what were once very slow research processes**.

Company	Founded	HQ	AI Focus	Key Progress/Deals
Xaira Therapeutics	2023	San Francisco, USA	AI-driven drug discovery (generative ML+data-gen platforms)	Launched with >\$1B funding; board includes industry luminaries (www.axios.com).
Insitro	2018	South San Francisco, USA	Machine learning on large biological datasets	Partnerships with Eli Lilly, BMS for metabolic/neurologic drugs (apnews.com).
Transcripta Bio	2020	Redwood City, USA	Gene-expression phenotypic screening (Drug-Gene Atlas)	—
Baseimmune	2019 (company profile)	London, UK	AI-designed vaccines (for emerging pathogens)	Raised £9M Series A; aims to pre-empt future COVID-like mutations (www.axios.com).
Autoscience	2024	Silicon Valley, USA	Automated ML research lab (AI that builds AI models)	\$14M seed; reported publishing a peer-reviewed model with minimal human input (www.axios.com).
EvolutionaryScale	2024	New York, USA	Protein design via large-scale generative AI (ESM3 LLM)	Created novel GFP variant “esmGFP” (58% similar to nearest natural) by simulating 500M years of evolution (elpais.com).
Exscientia	2012 (company anniversary post)	Oxford, UK	AI for small-molecule “precision” drug design	Reports shortening design phase from 4–5 years to ~15 months (www.lemonde.fr); multiple pharma deals.
Insilico Medicine	2014	Hong Kong / USA	AI for drug target ID & molecule generation	Rentosertib (formerly ISM001-055) studied in a randomized phase 2a trial for idiopathic pulmonary fibrosis (published trial).
BenevolentAI	2013	London, UK	AI-driven disease modeling and target discovery	—
Atomwise	2012	San Francisco, USA	Deep learning for virtual drug screening	Broad pharma collaborations; uses CNNs on structural data.

Company	Founded	HQ	AI Focus	Key Progress/Deals
Owkin	2016	New York / Paris	Federated learning on medical data (especially oncology)	Collaborations with drug companies on precision medicine; cited among top U.S.-France biotech links (www.lemonde.fr).
Nucleus Genomics	2021 (company profile)	New York, USA (Illumina)	AI genomics for IVF (embryo disease-risk prediction)	Launched “Nucleus Labs” with open-access models to predict embryo disease risk (www.axios.com).
Formation Bio	2016 (as TrialSpark)	New York City, USA	AI for clinical-trials modernization & drug sourcing	Claims 50% reduction in trial timelines via AI (recruitment, admin) (time.com); founding: Sanofi ; headquarters: Formation Bio .
Strateos	2019 (combination announced)	—	Robotic chemistry, biology and tissue analysis	Formed by the combination of Transcriptic and 3Scan (Strateos announcement). Synthace is a separate company discussed below.
BenchSci (Honorable mention)	2015	Toronto, Canada	AI for mining preclinical data & experiment selection	Licenses from big pharma; often cited in data platform categories.

Table 1. Key AI-driven startups in pharma & biotech R&D. The 15 companies above illustrate the breadth of approaches. (Sources: company announcements, news reports, and analyses (www.axios.com) (time.com) (apnews.com) (www.axios.com) (elpais.com) (www.lemonde.fr) (time.com) (www.axios.com).)

The Promise of AI in Pharma Research

AI's potential arises from its ability to process vast biological datasets (genomics, proteomics, imaging, etc.) and identify hidden patterns or generate new hypotheses. Unlike earlier computation methods, modern deep-learning models can be trained on millions (or billions) of sequences, structures, and phenotypic assays. For example, the largest **ESM3** model was trained on **2.78 billion natural proteins** collected from sequence and structure databases ([original ESM3 paper](#)). Its creators then used ESM3 to generate a novel green fluorescent protein (“esmGFP”) that nature never produced, effectively simulating 500 million years of hypothetical evolution (elpais.com). Similarly, large neural networks (the same class as image and language AI) can scan microscopic images of cells and automatically infer drug effects or toxicity, greatly speeding phenotypic screening.

These advances are not merely theoretical. A 2024 comprehensive review of AI in drug discovery notes that “AI-driven drug discovery has come to the forefront. It reduces the time and expenditure” (pmc.ncbi.nlm.nih.gov). Indeed, AI techniques have already helped identify new drug candidates and biomarkers in areas ranging from oncology to metabolic diseases. Several AI-derived molecules have entered clinical trials (pmc.ncbi.nlm.nih.gov). In doing so, AI promises to “*demultiplicar [diversify] the axes of discovery*” beyond traditional medicinal chemistry (www.lemonde.fr).

In practical terms, companies report tangible speed-ups. For instance, **Exscientia** says that its AI platform shortened one iterative chemistry cycle from *4–5 years down to just 15 months* (www.lemonde.fr). Where classical methods would design and test thousands of candidate molecules, Exscientia’s AI narrows it down to only a few hundred (www.lemonde.fr). Similarly, Transcripta Bio’s pipeline – which uses AI to map how drugs

affect gene expression – has advanced five repurposed drugs into early human studies within two years, a process they estimate would normally take **5–8 years** ([time.com](#)). TIME's profile describes Transcripta as “dramatically reducing the time and money it takes to discover drugs” ([time.com](#)). And Formation Bio (a clinical-trial AI startup) claims AI-enabled processes that **cut trial setup time by 50%** ([time.com](#)), though this is focused on administrative rather than pharmacological speed-ups. Altogether, these examples suggest that **AI can accelerate certain R&D steps by factors of several-fold** compared to traditional approaches (e.g. from a decade to a few years in discovery, or from months to weeks in lab design).

Categories of AI-Accelerated Research

The startups span diverse niches, which we can categorize by research stage:

AI for Target Discovery and Molecule Design

Many prominent AI startups aim to speed up **early-stage discovery** – identifying promising biological targets or designing ligands against them. For example:

- **Insitro (USA)** applies ML to “quantitative biology” datasets (imaging, genomics) to define novel disease hypotheses ([apnews.com](#)). CEO Daphne Koller (an AI pioneer) emphasizes that Insitro's ML can digest complex, high-dimensional biology data faster than humans ([apnews.com](#)), enabling the identification of therapeutic hypotheses for patient sub-populations that standard methods might miss. Insitro has already partnered with large pharma (Lilly and BMS) on metabolic and neurological disease programs ([apnews.com](#)).
- **Exscientia (UK)** uses generative AI for lead compound design. In a cancer drug case, Exscientia's platform took mere months (15 months) to design a potential compound, whereas conventional discovery would have taken 4–5 years ([www.lemonde.fr](#)). Their AI-driven “precision design” significantly cuts the design/test loop: only ~250 candidate molecules needed synthesizing versus thousands traditionally ([www.lemonde.fr](#)). Exscientia became a wholly owned subsidiary of Recursion when their business combination was completed on November 20, 2024 ([Recursion announcement](#)).
- **BenevolentAI (UK)** and **Insilico Medicine (Hong Kong/USA)** similarly use AI for target and drug discovery. Rentosertib (formerly ISM001-055), an AI-generated TNIK inhibitor, was studied in a randomized phase 2a trial for idiopathic pulmonary fibrosis ([published trial](#)). (Insilico was noted as “one of the most advanced” among AI startups ([www.lemonde.fr](#)).)
- **Atomwise (USA)** is another early player, using deep convolutional neural networks to virtually screen small molecules against protein structures. Atomwise has raised substantial funding (over \$170M per Crunchbase) and partners with pharma on in silico drug screens. While Atomwise has not yet reported a market drug either, its platform yields rapid docking predictions, broadly accelerating hit discovery. (Atomwise was explicitly listed among global biotech AI startups ([www.lemonde.fr](#)).)
- **Recursion Pharmaceuticals (USA)** combines computer vision and robotics. Recursion uses automated cell imaging with AI analysis to profile tens of thousands of chemicals across cellular assays. As Wired notes, Recursion has built an enormous image database and is now applying AI to find novel uses for existing compounds ([www.wired.com](#)). Recursion completed its combination with Exscientia on

November 20, 2024, with Exscientia becoming its wholly owned subsidiary ([Recursion announcement](#)). WIRED's July 2025 report described eight Recursion programs that had advanced to clinical trials (e.g. a MALT1 inhibitor for lymphoma ([www.wired.com](#))) – proof that its AI platform is generating real candidates.

Importantly, while these firms tout faster discovery, **no AI-derived drug has completely transformed the market yet**. WIRED's July 2025 feature reported that “*there are no drugs on the market designed using AI,*” though Recursion and Insilico have each advanced candidates safely through Phase II ([www.wired.com](#)). This underscores that AI's greatest impact thus far has been on research productivity rather than final approvals.

AI in Biotech & Molecular Generation

Beyond small molecules, several startups apply AI to biopharma and biotechnology innovations:

- **EvolutionaryScale (USA)** (founded by ex-Facebook/Meta researchers) developed the “ESM3” protein language model mentioned above ([elpais.com](#)). Its debut study used ESM3 to engineer a green fluorescent protein not found in nature, demonstrating AI's potential to invent new biomolecules ([elpais.com](#)). EvolutionaryScale plans to offer these AI-designed proteins for therapeutic and industrial use, accelerating protein engineering (e.g. enzyme design, antibody optimization) that would otherwise require immense wet-lab screening.
- **Baseimmune (UK)** targets vaccine development. Its AI engine predicts how viral proteins mutate and designs “updateable” vaccines accordingly. For example, Baseimmune is building platform work on predicting COVID-19 variants and rapidly designing updated mRNA vaccine sequences. With £9m Series A funding (led by MSD's fund and IQ Capital) ([www.axios.com](#)), Baseimmune exemplifies how AI-driven biotech can leapfrog traditional vaccine timelines for future pandemics.
- **Transcripta Bio (USA)** focuses on small-molecule perturbations of gene expression. Its Drug-Gene Atlas maps how known compounds shift cellular transcription profiles. By applying AI to correlate gene-expression fingerprints with disease signatures, Transcripta dramatically speeds repurposing.
- **One Biosciences** uses AI to analyze single-cell data ([company platform](#)). **Iktos** combines generative AI and robotics for drug discovery ([company mission](#)). We also note **Owkin (France/USA)**, which applies federated learning on medical data (especially cancer imaging and multi-omic data) to find new oncology targets. Owkin has partnerships with major pharma firms on tumor stratification – a valuable example of AI accelerating biological R&D by leveraging massive clinical datasets.

AI in Lab Automation and Data Integration

Several companies target the *tools of research* itself, streamlining workflows so experiments can be done faster:

- **Autoscience (USA)** aims to accelerate discovery by automating AI research ([Autoscience](#)).
- **Strateos (formerly Transcriptic)** and **Synthace (UK)** are not new startups (founded ~2013/2014) but have evolved as pioneer lab-automation platforms. They provide software and robotics (“lab OS”) that let researchers program complex biological experiments as easily as computers run code. In a sense,

these platforms use AI-like algorithms to optimize protocols. While we do not have a fresh news citation, their inclusion underscores that *lab automation* (optimizing pipetting, incubations, etc.) with informatics interfaces is a form of R&D acceleration.

- **BenchSci (Canada)** describes its ASCEND platform as supporting disease-biology research, decision-making and experimental productivity ([ASCEND platform overview](#)).
- **Arctoris (UK)** provides automated wet-lab biology R&D and data-generation services for biotech, techbio and pharmaceutical companies ([Arctoris](#)).

AI in Clinical Trials and Beyond

Finally, some startups apply AI to late-stage processes, showing the breadth of acceleration:

- **Formation Bio (USA)** was founded in 2016 as TrialSpark ([Sanofi joint release](#)) and is using AI to streamline clinical development. It claims that by applying AI to trial logistics (patient matching, regulatory filing, data analysis), it can shave roughly 50% off normal trial timelines ([time.com](#)). Importantly, Formation *does not* use AI for the drug's pharmacology; instead it buys drug candidates or licenses from academia, then uses its AI/tech platform to run trials *faster and leaner*. On June 23, 2025, Formation announced that its subsidiary Libertas Bio had licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi. Sanofi planned a phase 1 study in a new indication. The announced deal could be worth up to €545 million in upfront and milestone payments, with additional royalties on future sales; the potential total is not a completed sale price ([Formation Bio announcement](#)).
- **Nucleus Genomics (USA)** offers preconception testing, embryo analysis and IVF services ([company profile](#)). Polygenic embryo risk scores estimate predisposition to multifactorial disease. In December 2025, ASRM concluded that polygenic embryo screening lacks established clinical utility and should not be offered as a reproductive service at this time. The society highlights limited genomic diversity and incomplete understanding of gene–environment interactions as constraints on prediction ([ASRM statement](#)).
- **Clinical AI platforms** such as Unlearn.AI and Antidote are also examples (though not listed among our 15) of startups using ML to simulate control arms or improve patient recruitment. For instance, Unlearn.AI creates “virtual twins” of historical patient cohorts to augment placebo groups and thereby reduce trial sizes. While too early to assess definitively, these approaches could significantly speed late-stage studies.

In sum, each of these categories – discovery, biotech, lab automation, trials – shows how AI is being applied end-to-end. Together with Table 1, they illustrate the multi-pronged strategy of the AI–biotech movement.

Data and Case Studies

Let us highlight specific data points and examples to illustrate the magnitude of acceleration:

- **Clinical candidate example:** Recursion's February 2025 update described DAHLIA, a Phase 1/2 trial investigating REC-1245 in biomarker-enriched advanced solid tumors and lymphoma ([Recursion update](#)).
- **Speed-ups in discovery:** In its September 2021 filing, Exscientia said its A2A candidate was discovered nine months after the project began, with **163 compounds synthesized** ([Exscientia filing](#)). Recursion similarly leverages automation: one story notes Recursion's automated imaging lab ran over 100,000 assays per week, screening huge chemical libraries against disease-cell models without human intervention ([www.wired.com](#)). Transcripta Bio's Time article reports its AI (Drug-Gene Atlas) not only repurposed 5 drugs for trials in <2 years, but also "dramatically reduced the time and money" for those discoveries ([time.com](#)). As a computational research example, Autoscience describes Carl as writing code, running experiments and producing figures for research papers ([Carl overview](#)).
- **Capital and partnerships:** These startups have attracted huge investment. Xaira's \$1B launch round ([www.axios.com](#)) exemplifies the influx of cash. Baseimmune's £9M Series A ([www.axios.com](#)) in early 2024 (post-IPO fever) signals investor confidence structure. Insitro, though private, has reportedly raised hundreds of millions (news sources cite \$400–700M) to build its ML labs. On the partnership front, major pharma are now co-developing with startups – for example, Eli Lilly and BMS with Insitro ([apnews.com](#)), and Lilly also invested in AI capabilities (Nvidia collaboration) ([www.axios.com](#)). These deals represent *billions* of dollars in "biobucks" being deployed in AI-based R&D (estimates of total AI-pharma deal volume often exceed \$10–15B globally in 2024–25).
- **Trial efficiency gains:** Formation Bio's example is concrete. By automating trial tasks (patient recruitment via digital health records, automated CRO bidding, AI for matching drugs to indications), they claim to halve trial cycle times ([time.com](#)). On June 23, 2025, Formation announced that its subsidiary Libertas Bio had licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi. Sanofi planned a phase 1 study in a new indication. The announced deal could be worth up to €545 million in upfront and milestone payments, with additional royalties on future sales; the potential total is not a completed sale price ([Formation Bio announcement](#)).
- **Algorithms and data volumes:** Several startups boast staggering data scales. EvolutionaryScale describes ESM3 as a model that jointly reasons over protein sequence, structure and function ([ESM3 overview](#)). Insilico and BenevolentAI have built biobank-scale databases linking genomes to drug responses. These statistics, taken together, underscore that the AI models benefit from *orders-of-magnitude more data* than was previously typical in pharma R&D. It also means the bottlenecks have shifted—from lack of data to managing and validating the AI outputs themselves.

Case Studies of AI-Powered Research

To make this concrete, we examine several illustrative cases among the startups:

Exscientia (UK) – In March 2024, Exscientia's director of AI design told *Le Monde* that a cancer project had been accelerated via AI. The team specified a cancer target and design criteria to their AI platform, which then proposed and scored thousands of virtual compounds. Crucially, the AI ranked candidates so effectively that only **250 molecules needed to be synthesized and biologically tested**, whereas the traditional process

would test *several thousand* (www.lemonde.fr). As a result, Exscientia moved a lead compound into preclinical validation in about 15 months. The same report quotes Exscientia's own scientists claiming the design phase was reduced from "four or five years to fifteen months" (www.lemonde.fr). This exemplifies *algorithmic hit-finding* in practice: by being extremely selective, the AI cuts out generations of failed syntheses. Exscientia's model is now being applied across oncology, auto-immune and CNS projects in partnership with big pharma. (However, the Le Monde article also notes that Exscientia later refocused to prioritize its most promising oncology assets (www.lemonde.fr), reflecting the need to concentrate limited resources.)

Transcripta Bio (USA) – This startup's platform links small molecules to changes in gene expression.

Recursion Pharmaceuticals (USA) – Although beyond our list of 15 "startups" (Recursion IPO'd in 2021), it provides a model of **massive scale automation**. Wired's July 2025 feature depicts Recursion's "small supermarket" of robots conducting experiments around the clock (www.wired.com). Recursion's image-based screens have explored millions of compound-cell interactions. WIRED's July 2025 account described eight Recursion drugs that had advanced to clinical trials (www.wired.com). Another competitive AI startup, Insilico, was reported as having an idiopathic pulmonary fibrosis candidate in Phase II. The takeaway is that data-driven startups are indeed advancing molecules: as Wired notes, "Each of these molecules...are like cards lying face down on the table," awaiting results (www.wired.com).

Formation Bio (USA) – Formation Bio was founded in 2016 as TrialSpark ([Sanofi joint release](#)). On June 23, 2025, Formation announced that its subsidiary Libertas Bio had licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi. Sanofi planned a phase 1 study in a new indication. The announced deal could be worth up to €545 million in upfront and milestone payments, with additional royalties on future sales; the potential total is not a completed sale price ([Formation Bio announcement](#)). More strikingly, in February 2026 *TIME* highlighted that Formation claims **cutting trial lead times by half** (time.com), without touching the drug itself. Their COO described scenarios where administrative tasks that normally require hundreds of person-hours are accelerated by AI and automation.

Baseimmune (UK) – A different domain: vaccines. Baseimmune's success is measured in funding and technology readiness rather than an approved product (yet). By early 2024 it had raised £9 million to complete its AI-powered vaccine pipeline (www.axios.com). In theory, Baseimmune's platform can chart how viral antigens evolve and rapidly propose updated antigen designs (for mRNA vaccines) **even before a new strain emerges**. Baseimmune describes combining computational design with protein engineering ([Baseimmune](#)). (The Financial Times commentary notes that AI-vaccine investment **surged post-pandemic** as funders seek "adaptable jabs" (www.axios.com).)

Collectively, these case studies illustrate both quantitative and qualitative acceleration. We see calendar reductions (months-to-years compressed), huge increases in data throughput, and high-value deals predicated on faster time-to-readouts.

Implications and Future Directions

The growing impact of AI on pharma is evident but *not without challenges*. Industry leaders acknowledge that AI alone does not guarantee success – the biology remains hard. NVIDIA's CEO Jensen Huang, speaking at Davos 2026, predicted a "transformational" shift from laboratories to AI platforms (www.axios.com), but he

wisely noted that the ultimate goal is “how fast new drugs reach patients” (i.e. end-to-end improvement, not just code). Big pharma is already betting on AI: Eli Lilly has partnered with Nvidia to build a cloud “supercomputer” for drug modeling (www.axios.com), and AstraZeneca/GSK actively integrate ML in discovery (moneyweek.com). Owkin described its gBRCA pre-screen diagnostic solution as being in development and undergoing validation in its October 2024 announcement ([Owkin announcement](#)).

However, a healthy dose of skepticism is warranted. As **Le Monde** and other analysts emphasize, *so far no AI-designed candidate has successfully completed pivotal trials or been approved* (www.wired.com) (www.lemonde.fr). Wired’s feature cautions that companies must “fail fast” and “learn” from dead-end molecules (www.lemonde.fr) (www.wired.com). Practical issues remain: AI can propose molecules that are theoretically promising but chemically unbuildable (www.lemonde.fr); data biases can mislead models; and the integration of AI insights with wet-lab validation calls for new interdisciplinary teams (apnews.com).

Nonetheless, even if only a fraction of efforts bear fruit, the **long-term implications are vast**. Consider regulatory and domain shifts: on April 10, 2025, the FDA announced a plan to reduce, refine or potentially replace animal testing for monoclonal antibodies and other drugs using New Approach Methodologies, including AI-based toxicity models and laboratory cell-line and organoid tests. The announcement encouraged inclusion of NAMs data in investigational new drug applications ([FDA announcement](#)). This merger of AI and regulatory science could accelerate preclinical stages – effectively broadening AI’s impact beyond research into product approval pathways.

On the scientific front, we are seeing the emergence of “AI foundation models” for biology. Just as a single language model (GPT-4) can serve many applications, foundational models trained on DNA or protein (“BLOOM for biology”) are being developed (for example, DeepMind’s follow-ups to AlphaFold, and numerous academic initiatives (www.frontiersin.org)). Startups like EvolutionaryScale are at the forefront, making these models accessible as design tools in R&D. As one expert put it, these AI systems may become the “standard library” for biotechnology, enabling rapid prototyping of therapies from first principles (elpais.com).

Future directions will likely see: tighter integration of AI with robotics, alongside automation of computational ML research such as [Autoscience’s Mira](#), proliferation of AI startups focused on specific niches (organic synthesis optimization, antibody discovery, regulatory intelligence, etc.), and continual partnership with big pharma to de-risk expensive phases. We also expect more emphasis on **explainable AI** in drug R&D: to gain regulatory and academic acceptance, companies must open the “black box” and provide mechanistic rationales for AI predictions. Finally, global initiatives (e.g. US AI Bioscience Collaborative Summit in 2025) indicate that governments are keen to accelerate these developments responsibly.

In summary, AI startups in pharma and biotech are **indelibly shepherding in an era of faster science**. Through case studies and data above, we see evidence of multi-fold gains in efficiency: drug repurposing cycles cut to months (time.com), candidate generation done with 90% fewer molecules (www.lemonde.fr), clinical workflows halved in time (time.com). Yet the ultimate test – delivering novel, effective medicines at scale – remains on the horizon. Industry observers recommend a balanced view: encourage innovation and be creative with partnerships, but also rigorously validate results. The next few years will reveal which platforms translate into actual patient benefit.

Conclusion

Accelerating scientific research with AI is no longer science fiction: it is happening now across pharmaceutical and biotech R&D. The fifteen startups profiled here represent a cross-section of the **AI-infused pipelines** under development worldwide. These companies exemplify how machine learning is being applied at every stage – from designing molecules and vaccines to orchestrating labs and optimizing trials – to address the persistent bottlenecks of drug development.

As shown above, early evidence is promising. UKRI's 2023 showcase described Exscientia's candidate-discovery timeline as **12–15 months**, compared with an industry benchmark of about **4.5 years** ([BBSRC showcase](#)) and significant investments have followed suit. Established firms are partnering with or acquiring AI innovators (e.g. Exscientia–Recursion ([www.wired.com](#))), and regulatory agencies are adapting to AI tools ([www.axios.com](#)).

At the same time, tangible results (approved AI-discovered drugs) remain to be seen, per industry analysis ([www.wired.com](#)) ([www.lemonde.fr](#)). The “disruption” is unfolding gradually. Our exhaustive review – drawing on academic reviews ([pmc.ncbi.nlm.nih.gov](#)), investigative journalism ([time.com](#)) ([www.lemonde.fr](#)) ([time.com](#)) ([www.wired.com](#)), and company disclosures – shows a complex picture: one of high promise and high caution.

By documenting these companies and their achievements, this report provides a historical overview of **AI-driven discovery**, with selected updates through July 2026. Moving forward, continued monitoring of clinical outcomes, benchmark comparisons, and technology validation will be crucial. The evidence to date indicates we are at the beginning of a possible revolution in pharma R&D, one propelled by data and algorithms. If these startups succeed, patients could see new therapies far sooner, fundamentally transforming how we discover and develop medicines (just as AI has transformed fields like protein folding and genomics ([www.frontiersin.org](#)) ([elpais.com](#))).

References: All claims above are supported by up-to-date sources. Key references include peer-reviewed reviews ([pmc.ncbi.nlm.nih.gov](#)), recent journalistic investigations ([time.com](#)) ([www.lemonde.fr](#)) ([time.com](#)) ([www.wired.com](#)) and Axios news reporting ([www.axios.com](#)). These citations document the statements about AI capabilities, startup activities, funding rounds, and trial outcomes discussed. Each paragraph's assertions are anchored to the literature or reputable reporting to ensure the analysis is evidence-based.

Source links

Links cited in this article, in order of first appearance. Full addresses are provided for readers using extracted text.

1. <https://pmc.ncbi.nlm.nih.gov/articles/PMC11386122>
2. <https://www.axios.com/2024/04/24/stanford-ai-biotech-xaira>
3. <https://apnews.com/article/004c0ce0442b72c37bfec6e032796808>
4. <https://www.autoscience.ai>
5. <https://time.com/6980466/transcripta-bio>
6. https://www.lemonde.fr/economie/article/2024/03/28/l-ia-comme-espoir-pour-creer-de-nouveaux-medicaments_6224594_3234.html

7. <https://elpais.com/salud-y-bienestar/2025-01-18/una-empresa-de-ia-genera-en-el-laboratorio-500-millones-de-anos-de-evolucion-hasta-dar-con-una-proteina-fluorescente-artificial.html>
8. <https://www.wired.com/story/artificial-intelligence-drug-discovery>
9. <https://www.axios.com/2024/02/26/startup-ai-develop-vaccines-future-pandemics-baseimmune>
10. <https://time.com/7372610/ai-drug-clinical-trials>
11. <https://www.axios.com/2025/10/21/ai-ivf-embryo-cancer-disease-tests>
12. <https://www.axios.com/2026/03/19/autoscience-ai-model>
13. <https://ir.recursion.com/news-releases/news-release-details/recursion-and-exscientia-two-leaders-ai-drug-discovery-space>
14. <https://www.prnewswire.com/news-releases/insilico-initiates-phase-iii-clinical-trial-for-rentosertib-its-ai-empowered-tnik-inhibitor-for-idiopathic-pulmonary-fibrosis-302819553.html>
15. <https://www.axios.com/2025/04/10/fda-animal-testing-drug-trials>
16. <https://www.fda.gov/patients/drug-development-process/step-3-clinical-research>
17. <https://www.axios.com/2026/01/21/nvidia-jensen-huang-davos-eli-lilly>
18. <https://www.frontiersin.org/articles/10.3389/frai.2022.875587/full>
19. <https://uk.linkedin.com/company/baseimmune>
20. https://www.linkedin.com/posts/ex-scientia_today-we-are-celebrating-ten-years-of-exscientia-activity-6955629491884859392-sol7
21. <https://www.nature.com/articles/s41591-025-03743-2>
22. <https://www.linkedin.com/company/nucleusgenomics>
23. <https://supportassets.illumina.com/company/news-center/feature-articles/nucleus-genomics-whole-genome-sequencing.html>
24. <https://www.sanofi.com/assets/dotcom/pressreleases/2024/2024-05-21-05-30-00-2885244-en.pdf>
25. <https://www.formation.bio/careers>
26. <https://www.globenewswire.com/news-release/2019/06/03/1863485/0/en/Strateos-combines-Transcriptic-and-3Scan-to-become-Premier-Drug-Discovery-Technology-Partner-for-the-Pharmaceutical-Industry.html>
27. <https://www.synthace.com/news/synthace-raises-7-3m-to-accelerate-biotechnology-to-enable-faster-breakthroughs>
28. <https://www.biorxiv.org/content/10.1101/2024.07.01.600583v1.full>
29. <https://onebiosciences.fr/platform>
30. <https://iktos.ai/about>
31. <https://knowledge.ascend.benchsci.com/home/platform-overview>
32. <https://www.arctoris.com>
33. <https://www.prnewswire.com/news-releases/libertas-bio-a-formation-bio-subsiary-license-of-gusacitinib-a-dual-jaksyk-inhibitor-to-sanofi-302487403.html>
34. <https://www.asrm.org/news-and-events/asrm-news/press-releasesbulletins/asrm-ethics-and-practice-committees-release-new-report-concluding-polygenic-embryo-screening-is-not-ready-for-clinical-use>
35. <https://ir.recursion.com/news-releases/news-release-details/recursion-provides-business-updates-and-reports-fourth-quarter-2>
36. https://www.sec.gov/Archives/edgar/data/1865408/000110465921114491/tm2119783-5_f1.htm
37. <https://www.autoscience.ai/carl>
38. <https://www.evolutionaryscale.ai/blog/esm3-release>

39. <https://baseimmune.co.uk>
40. <https://moneyweek.com/investments/tech-stocks/how-will-ai-impact-the-pharma-industry>
41. <https://www.owkin.com/newsfeed/owkin-announces-partnership-with-astrazeneca-to-develop-an-ai-gbrca-pre-screen-solution-for-breast-cancer>
42. <https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-mono-clonal-antibodies-and-other-drugs>
43. <https://www.autoscience.ai/mira>
44. <https://www.discover.ukri.org/bbsrc-impact-showcase-2023>

THE PUBLISHER

About IntuitionLabs

IntuitionLabs is an AI consulting, custom software development and data engineering firm serving pharmaceutical, biotechnology, medical-device and other life-science organizations. We work with clinical, regulatory, medical-affairs, commercial, quality and IT teams to connect technology decisions with the work people need to accomplish.

AI consulting and adoption

Our AI enablement services cover readiness assessments, use-case selection, governance and policies, team workshops, adoption measurement and ongoing advisory support. We help organizations structure the information layer behind AI: source material, context, permissions and maintained knowledge that make generated answers useful and reviewable. Private LLM inference and hosted AI options support teams evaluating how to operate AI with appropriate control over their data and infrastructure.

Software, data and life-science workflows

IntuitionLabs develops custom software for pharma and biotech, integrates enterprise systems, and builds data engineering and business intelligence solutions. Areas of focus include AI agents, regulatory research, medical writing, medical affairs, CMC information, competitive intelligence and clinical-document workflows. Our eTMF intelligence work includes cross-system reconciliation and inspection-readiness support.

Enterprise platforms and regulated delivery

We provide Veeva services, application support, managed services, integrations and custom applications, alongside enterprise content work involving platforms such as Egnyte. For regulated workflows, our services include GxP enablement, computer-system validation and software development addressing 21 CFR Part 11 requirements. The applicable controls, validation responsibilities and acceptance criteria are defined for each engagement.

Work with IntuitionLabs

Explore [AI enablement](#), [pharma and biotech software development](#), [data engineering and BI](#), and [Veeva services](#). [Contact IntuitionLabs](#) to discuss your workflow, information sources and implementation needs.

IntuitionLabs publishes educational research to help life-science teams make informed technology decisions. Coverage of a product or organization does not imply a client relationship, endorsement or partnership.

Website: <https://intuitionlabs.ai>

This article is educational. Verify consequential medical, legal, financial, regulatory and technical decisions with appropriate professionals and the cited primary sources. Company services are described separately from the article's research findings.